Fig. 3: Treatment with CP-673451 reduces proliferation and invasiveness of GBM cells and patient-derived GSCs.
From: PDGF-R inhibition induces glioblastoma cell differentiation via DUSP1/p38MAPK signalling
A Proliferation assay (crystal violet) was performed on U87 GBM cells and patient-derived GSCs GS090 and G179 treated with increasing concentrations of CP-673451 (0, 1, 5 and 10 μM). Values normalised to DMSO control. B HA-based 3D assay was performed on U87, U138, GS090 and G179. Cells were seeded into the HA-based assay and incubated for 48 h before beginning CP-673451 treatment at increasing concentrations (0, 1, 5 and 10 µM). Fresh treatment was applied every 2 days. Images were taken at 10x mag on day 7 of treatment and the (B) areas and (C) numbers of colonies were measured and normalised to DMSO control. D Representative images are shown, Scale bar = 200 μm. E Viability assay (CellTiter-Glo) was then performed. Values normalised to DMSO control. The mean ± SD of minimum n = 3 independent experiments is displayed, representative images shown *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001 and ****p ≤ 0.0001 (two-tailed t-test).
